BTIG Research Has Lowered Expectations for Outset Medical (NASDAQ:OM) Stock Price

Outset Medical (NASDAQ:OM) had its price target reduced by equities research analysts at BTIG Research from $39.00 to $17.00 in a note issued to investors on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. BTIG Research’s price target would suggest a potential upside of 40.85% from the company’s current price.

Several other analysts have also weighed in on the company. Stifel Nicolaus set a $14.00 target price on Outset Medical in a report on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Outset Medical in a research report on Wednesday, October 8th. Finally, Royal Bank Of Canada reissued a “sector perform” rating and issued a $22.00 price objective on shares of Outset Medical in a research note on Tuesday, August 19th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $17.67.

Outset Medical Trading Up 0.1%

Shares of Outset Medical stock opened at $12.07 on Tuesday. The company has a 50-day moving average of $13.94 and a two-hundred day moving average of $15.89. Outset Medical has a 12-month low of $5.85 and a 12-month high of $25.35. The company has a current ratio of 7.47, a quick ratio of 6.05 and a debt-to-equity ratio of 0.63. The stock has a market cap of $214.48 million, a PE ratio of -0.59 and a beta of 2.14.

Outset Medical (NASDAQ:OM) last announced its quarterly earnings results on Monday, November 10th. The company reported ($0.98) EPS for the quarter, missing the consensus estimate of ($0.64) by ($0.34). Outset Medical had a negative return on equity of 97.17% and a negative net margin of 82.06%. Outset Medical has set its FY 2025 guidance at EPS. On average, research analysts anticipate that Outset Medical will post -1.99 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Legal & General Group Plc purchased a new stake in Outset Medical in the second quarter valued at approximately $34,000. Ameritas Investment Partners Inc. acquired a new position in shares of Outset Medical in the 2nd quarter valued at $35,000. BNP Paribas Financial Markets grew its stake in shares of Outset Medical by 7,013.8% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,063 shares of the company’s stock valued at $40,000 after buying an additional 2,034 shares during the period. Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of Outset Medical during the 2nd quarter worth $78,000. Finally, New York State Common Retirement Fund acquired a new stake in shares of Outset Medical during the 2nd quarter worth $108,000.

Outset Medical Company Profile

Outset Medical, Inc, a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.